Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Protective T Cell and Antibody Immune Responses against Hepatitis C Virus Achieved Using a Biopolyester-Bead-Based Vaccine Delivery System.

Martínez-Donato G, Piniella B, Aguilar D, Olivera S, Pérez A, Castañedo Y, Alvarez-Lajonchere L, Dueñas-Carrera S, Lee JW, Burr N, Gonzalez-Miro M, Rehm BH.

Clin Vaccine Immunol. 2016 Apr 4;23(4):370-8. doi: 10.1128/CVI.00687-15. Print 2016 Apr.

2.

Innate and Adaptive Immune Responses in Chronic HCV Infection.

Dustin LB.

Curr Drug Targets. 2017;18(7):826-843. doi: 10.2174/1389450116666150825110532.

3.

Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity.

Kachko A, Frey SE, Sirota L, Ray R, Wells F, Zubkova I, Zhang P, Major ME.

Hepatology. 2015 Dec;62(6):1670-82. doi: 10.1002/hep.28108. Epub 2015 Oct 16.

4.

Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, Challenge.

Bukh J, Engle RE, Faulk K, Wang RY, Farci P, Alter HJ, Purcell RH.

J Virol. 2015 Sep;89(17):9128-32. doi: 10.1128/JVI.01194-15. Epub 2015 Jun 17.

5.

Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Kong L, Jackson KN, Wilson IA, Law M.

Curr Opin Virol. 2015 Apr;11:148-57. doi: 10.1016/j.coviro.2015.04.001. Epub 2015 Apr 29. Review.

6.

The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development.

Cashman SB, Marsden BD, Dustin LB.

Front Immunol. 2014 Nov 10;5:550. doi: 10.3389/fimmu.2014.00550. eCollection 2014. Review.

7.

Contradictory immune response in post liver transplantation hepatitis B and C.

Takaki A, Yagi T, Yamamoto K.

Int J Inflam. 2014;2014:814760. doi: 10.1155/2014/814760. Epub 2014 Aug 24. Review.

8.

Immune control and failure in HCV infection--tipping the balance.

Dustin LB, Cashman SB, Laidlaw SM.

J Leukoc Biol. 2014 Oct;96(4):535-48. doi: 10.1189/jlb.4RI0214-126R. Epub 2014 Jul 11. Review.

9.

The past, present and future of neutralizing antibodies for hepatitis C virus.

Ball JK, Tarr AW, McKeating JA.

Antiviral Res. 2014 May;105:100-11. doi: 10.1016/j.antiviral.2014.02.013. Epub 2014 Feb 26. Review.

10.

A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81.

Zhao Z, Zhong L, Elrod E, Struble E, Ma L, Yan H, Harman C, Deng L, Virata-Theimer ML, Liu P, Alter H, Grakoui A, Zhang P.

PLoS One. 2014 Jan 6;9(1):e84346. doi: 10.1371/journal.pone.0084346. eCollection 2014.

11.

Sequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host.

D'Arienzo V, Moreau A, D'Alteroche L, Gissot V, Blanchard E, Gaudy-Graffin C, Roch E, Dubois F, Giraudeau B, Plantier JC, Goudeau A, Roingeard P, Brand D.

J Virol. 2013 Dec;87(24):13609-18. doi: 10.1128/JVI.02119-13. Epub 2013 Oct 9.

12.

Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles.

Deng Y, Guan J, Wen B, Zhu N, Chen H, Song J, Yang Y, Wang Y, Tan W.

PLoS One. 2013 Apr 23;8(4):e62684. doi: 10.1371/journal.pone.0062684. Print 2013.

13.

High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.

Gómez CE, Perdiguero B, Cepeda MV, Mingorance L, García-Arriaza J, Vandermeeren A, Sorzano CÓ, Esteban M.

J Virol. 2013 Jul;87(13):7282-300. doi: 10.1128/JVI.03246-12. Epub 2013 Apr 17.

14.

Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein.

Duan H, Kachko A, Zhong L, Struble E, Pandey S, Yan H, Harman C, Virata-Theimer ML, Deng L, Zhao Z, Major M, Feinstone S, Zhang P.

J Virol. 2012 Dec;86(23):12686-94. doi: 10.1128/JVI.00994-12. Epub 2012 Sep 12.

15.

Prevention of hepatitis C recurrence after liver transplantation: An update.

Carbone M, Lenci I, Baiocchi L.

World J Gastrointest Pharmacol Ther. 2012 Aug 6;3(4):36-48. doi: 10.4292/wjgpt.v3.i4.36.

16.

Hepatitis C virus evasion mechanisms from neutralizing antibodies.

Di Lorenzo C, Angus AG, Patel AH.

Viruses. 2011 Nov;3(11):2280-300. doi: 10.3390/v3112280. Epub 2011 Nov 15. Review.

17.

Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies.

Ashfaq UA, Qasim M, Yousaf MZ, Awan MT, Jahan S.

J Transl Med. 2011 Nov 10;9:194. doi: 10.1186/1479-5876-9-194.

18.

The hepatitis C virus glycan shield and evasion of the humoral immune response.

Helle F, Duverlie G, Dubuisson J.

Viruses. 2011 Oct;3(10):1909-32. doi: 10.3390/v3101909. Epub 2011 Oct 14. Review.

19.

Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives.

Major ME.

Viruses. 2009 Sep;1(2):144-65. doi: 10.3390/v1020144. Epub 2009 Aug 12.

20.

Antibody V(h) repertoire differences between resolving and chronically evolving hepatitis C virus infections.

Racanelli V, Brunetti C, De Re V, Caggiari L, De Zorzi M, Leone P, Perosa F, Vacca A, Dammacco F.

PLoS One. 2011;6(9):e25606. doi: 10.1371/journal.pone.0025606. Epub 2011 Sep 28.

Supplemental Content

Support Center